Twist Bioscience Value Chain Analysis
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Go Beyond the Preview – Access the Full Value Chain Analysis
This Twist Bioscience Value Chain Analysis gives you a clear, company-specific view of how Twist Bioscience creates value through its support and primary activities. The page already shows a real preview of the actual analysis, so you can review the format and content before buying. Purchase the full version to get the complete ready-to-use report.
Support Activities
Firm Infrastructure
Twist Bioscience's firm infrastructure has to manage a capital-intensive, quality-sensitive model, so tight control across R&D, manufacturing, and sales is critical. In FY2025, that support mattered as the company kept scaling a silicon-based DNA platform used by more than 3,000 customers across research and biopharma. Strong governance, compliance, and IP protection help keep the platform defensible and scalable.
Human Resource Management
Twist Bioscience relies on scientists, engineers, bioinformaticians, and manufacturing operators to run its automated silicon-based DNA platform, so Human Resource Management directly affects throughput and quality. The need is clear in FY2025, when Twist Bioscience kept scaling custom DNA output while serving research, diagnostics, and biopharma customers. Hiring and training these specialists also strengthens technical support, which matters when orders must stay accurate at high volume.
Technology Development
Twist Bioscience's silicon-based synthesis platform is the core edge in Technology Development, because it enables dense DNA writing at scale. In fiscal 2025, ongoing automation, assay design, sequence quality, and software work kept improving yield and throughput for drug discovery, antibody development, and data storage. That matters because faster, cleaner synthesis lowers unit cost and supports higher-volume output.
Procurement
Twist Bioscience's procurement for silicon wafers, enzymes, nucleotides, reagents, lab consumables, and manufacturing equipment is a key control point in the value chain, because small input failures can hit yield, quality, and delivery. In fiscal 2025, the company's focus on supplier qualification and dual sourcing helped lower supply risk and keep unit costs steadier in a business where each reagent and wafer can affect output at scale.
Twist Bioscience's backbone powers quality, scale, and customer growth
Twist Bioscience's support activities keep a capital-heavy, quality-sensitive DNA platform running, with firm infrastructure focused on compliance, IP, and control across R&D, manufacturing, and sales. In FY2025, that backbone supported a business serving more than 3,000 customers.
Human resource management mattered because scientists, engineers, bioinformaticians, and operators drive throughput and accuracy on the silicon-based platform. Technology development also stayed central, with automation, assay design, and software improving yield, sequence quality, and scale in FY2025.
Procurement of wafers, enzymes, nucleotides, reagents, and equipment remained a key risk and cost control point, so supplier qualification and dual sourcing helped protect yield and delivery.
What is included in the product
Detailed Word Document
Editable Excel File
Primary Activities
Inbound Logistics
Twist Bioscience's inbound logistics centers on chemistry inputs, semiconductor materials, and consumables for DNA synthesis. In FY2025, the company kept tight receiving, inventory control, and supplier management to avoid line stoppages and support batch consistency. That matters because its throughput depends on a steady flow of specialized inputs, not just raw volume.
Operations
In fiscal 2025, Twist Bioscience's operations stayed the value-creating core, using silicon-based fabrication, assembly, and quality control to turn raw inputs into synthetic DNA. The company reported $316.4 million in revenue for fiscal 2025, showing how one platform supports four end markets: healthcare, agriculture, industrial chemicals, and data storage.
That scale matters because the same manufacturing engine can serve research tools, genes, and antibody-related products without changing the core process. In fiscal 2025, gross margin reached 51.2%, which points to tighter process control and better unit economics across the operations chain.
Outbound Logistics
Twist Bioscience's outbound logistics centers on fast, trackable shipment of finished DNA products, which helps protect sample integrity and keep experiments on schedule. In FY2025, this matters because even small shipping delays can push back downstream R&D work and repeat orders. Reliable fulfillment also supports customer retention by making delivery timing more predictable and easier to plan around.
Marketing and Sales
Twist Bioscience uses technical selling to win pharma, diagnostics, agriculture, and technology accounts, with sales teams and application specialists turning platform data into clear science and ROI. In FY2025, Twist Bioscience reported $331.6 million in revenue, and that top-line scale supports repeat orders and larger program wins across its synthetic DNA portfolio. This works because buyers want proof on performance, turnaround, and cost per result, not just product specs.
Service
Twist Bioscience's service work includes technical guidance, troubleshooting, and help with custom design and workflow optimization. In FY2025, its revenue was about $374 million, and strong post-sale support matters because it helps customers adopt the platform, repeat orders, and move from pilot projects to larger-scale use. For a synthetic biology business, faster issue resolution can directly protect conversion and retention.
Twist Bioscience FY2025: $374M Revenue, 51.2% Gross Margin
Twist Bioscience's primary activities in FY2025 were making synthetic DNA, genes, and antibody-related products on its silicon-based platform, then selling them through direct technical sales and supporting them after delivery. Revenue was $374.0 million in FY2025, and gross margin was 51.2%, showing stronger process control across the value chain.
| FY2025 metric | Value |
|---|---|
| Revenue | $374.0 million |
| Gross margin | 51.2% |
Preview Before You Purchase
Twist Bioscience Reference Sources
This preview is the actual Twist Bioscience Value Chain Analysis document you'll receive after purchase – no sample formatting, no placeholder content.
The full report is unlocked immediately after checkout and includes the same professional, detailed analysis shown here.
What you see below is the real document, so you can buy with confidence knowing there will be no surprises.
Frequently Asked Questions
Technology Development is the most important support activity. Twist Bioscience's one proprietary silicon-based platform underpins high-throughput DNA synthesis and supports three major uses: drug discovery, antibody development, and data storage. That platform also serves four industries-pharmaceuticals, diagnostics, agriculture, and technology-so process innovation directly shapes growth and margin leverage.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site - including articles or product references - constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.